寄生虫与医学昆虫学报2025，Vol.32Issue(1)：52-59,8.DOI:10.3969/j.issn.1005-0507.2025.01.010
抗弓形虫药物研究进展:现状、方向及挑战
PROGRESS IN ANTI-TOXOPLASMA GONDII DRUG DEVELOPMENT:CURRENT STATUS,DIRECTION,AND CHALLENGES
摘要
Abstract
Toxoplasma gondii is an opportunistic pathogenic protozoan that causes zoonotic toxoplasmosis and is capable of infecting almost all warm-blooded animals,including humans.T.gondii infection is a globally prevalent zoonosis,posing a particularly high risk to immunocompromised populations.It presents a serious threat to public health and animal husbandry due to its complex life cycle and wide host range.Currently,the prevention and treatment of toxoplasmosis rely primarily on drugs,with a combination of sulfadiazine and pyrimethamine being the first choice in clinical practice.However,limitations in efficacy,side effects,and drug resistance restrict its widespread use.While some progress has been made in the development of anti-Toxoplasma drugs,no ideal treatment has yet been approved for market release or clinical trials.This paper reviews recent progress on the mechanisms of action and targets of novel anti-Toxoplasma drugs based on relevant studies.It aims to provide new ideas for future drug research and development while highlighting the opportunities and challenges in the field.关键词
弓形虫/抗弓形虫药物/作用机制/药靶Key words
Toxoplasma gondii/Anti-Toxoplasma drugs/Mechanism of action/Drug targets分类
医药卫生引用本文复制引用
赖映梅,卓洵辉,金子..抗弓形虫药物研究进展:现状、方向及挑战[J].寄生虫与医学昆虫学报,2025,32(1):52-59,8.基金项目
浙江省中医药科技计划项目(2022ZQ059) （2022ZQ059）
杭州医学院院所专项(YS2021008) （YS2021008）
杭州医学院科研启动经费(00004F1RCYJ2012) （00004F1RCYJ2012）
